-
Mashup Score: 73
We report long-term outcomes from a pooled analysis of patients with previously untreated metastatic non‒small-cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) <1% enrolled in phase 3 studies of pembrolizumab plus chemotherapy versus placebo plus chemotherapy.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 72
We report long-term outcomes from a pooled analysis of patients with previously untreated metastatic non‒small-cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) <1% enrolled in phase 3 studies of pembrolizumab plus chemotherapy versus placebo plus chemotherapy.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Increasingly Targeted ADCs Drive NSCLC Treatment Innovations - 5 day(s) ago
Shirish M, Gadgeel, MD, highlights key treatment advances achieved with antibody-drug conjugates in non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Increasingly Targeted ADCs Drive NSCLC Treatment Innovations - 7 day(s) ago
Shirish M, Gadgeel, MD, highlights key treatment advances achieved with antibody-drug conjugates in non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2FDA Approves Alecensa for ALK-Positive NSCLC - 7 day(s) ago
The Food and Drug Administration approved Alecensa for patients with ALK-positive non-small cell lung cancer that was surgically removed.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 2Radiation, Durvalumab, and Chemo Improve Survival in ES-SCLC - 9 day(s) ago
Adding low-dose radiotherapy to standard-of-care durvalumab and chemotherapy led to survival benefits among patients with extensive-stage small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Patient Scenario 1: Newly Diagnosed ES-SCLC With Presence of Hepatic and Brain Metastases - 13 day(s) ago
A panel of expert oncologists present the case of a 68-year-old man with newly diagnosed, extensive stage small-cell lung cancer and brain metastases, who is treated with carboplatin, etoposide, and durvalumab, and provide their initial impressions.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Increasingly Targeted ADCs Drive NSCLC Treatment Innovations - 13 day(s) ago
Shirish M, Gadgeel, MD, highlights key treatment advances achieved with antibody-drug conjugates in non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 56
Correlations of overall response rate and progression-free survival with overall survival were generally moderate in this pooled analysis. The findings support routine analysis of mature overall survival data, where feasible, in first-line randomised trials of ICIs for metastatic NSCLC.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
There is currently 1 FDA-approved antibody-drug conjugate available for patients with non-small cell lung cancer, and several more potentially coming down the pike.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Pooled 5-yr outcomes of Pembro+Chemo for PDL1<1% metastatic NSCLC @JTOonline: - 442pts (KN189, KN407 &China/Japan extensions) - mOS 0.64, mPFS HR 0.66, 5yr OS 12.5 v 9.3% favors chemo-IO - g3+ TRAEs 59.1% chemo-IO @IASLC @OncoAlert @ShirishGadgeel #LCSM https://t.co/tJE1u4cEhM